Advertisement
Advertisement
U.S. Markets open in 8 hrs 52 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.75+0.24 (+2.09%)
At close: 04:00PM EDT
11.53 -0.22 (-1.87%)
After hours: 07:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.51
Open11.46
Bid0.00 x 900
Ask0.00 x 900
Day's Range11.40 - 11.85
52 Week Range7.40 - 18.93
Volume321,031
Avg. Volume499,798
Market Cap628.14M
Beta (5Y Monthly)1.08
PE Ratio (TTM)24.53
EPS (TTM)0.48
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • Zacks

    Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cara Therapeutics Reports Second Quarter 2022 Financial Results

    – Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI

  • Zacks

    Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

    Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Advertisement
Advertisement